NR 566 FINAL EXAM 2026/2027 | COMPREHENSIVE NURSING QUESTIONS & ANSWERS | L…
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR 566 Final Exam
2026/2027 | Comprehensive
Nursing Questions &
Answers | Latest Course
Exam Review (Rationales)
Verified Answers Exam Ready With Rationales 107 QUESTIONS
DOCUMENT OVERVIEW
This comprehensive review document offers 107 nursing exam questions, each paired with
its correct answer and detailed rationales, covering advanced pharmacology and women's
health topics. It is an ideal resource for in-depth study, thorough course review, and
certification examination preparation.
TOPICS
• Reproductive Health & Hormonal • Neurological Disorders: Parkinson's &
Therapy Alzheimer's
• Migraine Management • Mood Disorders &
Psychopharmacology
• Anxiety Disorders & Sedatives • Herbal Supplements & Interactions
Page 1
, E XA M Q U EST I O N S
Q1 QUESTION 1 OF 107
Raloxifene (Evista) and bisphosphonates (alendronate, calcitonin)
RESPONSE
alternatives for hormone replacement therapy
RATIONALE
These medications are used as alternatives to hormone replacement therapy (HRT) for managing
osteoporosis. They work by inhibiting bone resorption, thereby preserving bone mineral density
and reducing fracture risk in postmenopausal women.
Q2 QUESTION 2 OF 107
Selective Estrogen Receptor Modulators (SERMs)
RESPONSE
Tamoxifen, toremifene, raloxifene -- provide estrogen benefits while avoiding its drawbacks
RATIONALE
Selective Estrogen Receptor Modulators (SERMs) are a class of drugs that exhibit tissue-specific
estrogenic or anti-estrogenic effects. They are exemplified by tamoxifen, toremifene, and
raloxifene, which act to provide beneficial estrogenic effects in some tissues while concurrently
blocking detrimental estrogenic actions in others. This dual action allows for therapeutic benefits
with reduced side effects.
Q3 QUESTION 3 OF 107
Dysfunctional uterine bleeding
RESPONSE
10-14 day course of progestin
Page 2
, RATIONALE
Progestin therapy is the cornerstone for managing dysfunctional uterine bleeding by stabilizing the
endometrium and preventing further excessive shedding. A 10-14 day course is typically prescribed
to restore hormonal balance and regulate the menstrual cycle. This intervention aims to reduce
bleeding volume and duration.
Q4 QUESTION 4 OF 107
Amenorrhea treatment
RESPONSE
progestin helps induce menstrual flow
RATIONALE
Progestin mimics the effects of progesterone, leading to the proliferation and subsequent
shedding of the uterine endometrium. This cyclical breakdown and shedding of the endometrium is
the physiological mechanism that results in menstrual flow, thereby inducing menstruation in cases
of amenorrhea.
Q5 QUESTION 5 OF 107
Amenorrhea estrogen levels are low
RESPONSE
give progestin for 5-10 days
RATIONALE
Low estrogen levels in amenorrhea indicate a hypogonadal state, often associated with
hypothalamic amenorrhea or premature ovarian failure. Administration of progestin for 5-10 days is
a diagnostic and therapeutic trial to assess for withdrawal bleeding, confirming adequate
endometrial proliferation from endogenous estrogen. If bleeding occurs, it suggests sufficient
estrogen priming.
Q6 QUESTION 6 OF 107
Long term progestin therapy
Page 3
, RESPONSE
protection against endometrial cancer
RATIONALE
Continuous progestin therapy opposes the proliferative effects of unopposed estrogen on the
endometrium. This antagonism prevents endometrial hyperplasia, thereby offering protection
against endometrial cancer in women receiving hormone therapy.
Q7 QUESTION 7 OF 107
Estradiol
RESPONSE
most active estrogenic compound. oral estrogen option
RATIONALE
Estradiol is the primary and most potent endogenous estrogen, responsible for most estrogenic
effects. It is also available as an oral medication for hormone replacement therapy.
Q8 QUESTION 8 OF 107
Advantages of estrogen transdermal patch
RESPONSE
lower total estrogen dose. less n/v. less fluctuation of estrogen blood levels. lower r/f DVT, PE
and stroke
RATIONALE
Transdermal estrogen delivery bypasses first-pass hepatic metabolism, allowing for a lower total
dose and reduced gastrointestinal side effects like nausea and vomiting. This route also provides
more stable serum estrogen levels and is associated with a decreased risk of thromboembolic
events and stroke compared to oral administration.
Q9 QUESTION 9 OF 107
Femring
Page 4
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR 566 Final Exam
2026/2027 | Comprehensive
Nursing Questions &
Answers | Latest Course
Exam Review (Rationales)
Verified Answers Exam Ready With Rationales 107 QUESTIONS
DOCUMENT OVERVIEW
This comprehensive review document offers 107 nursing exam questions, each paired with
its correct answer and detailed rationales, covering advanced pharmacology and women's
health topics. It is an ideal resource for in-depth study, thorough course review, and
certification examination preparation.
TOPICS
• Reproductive Health & Hormonal • Neurological Disorders: Parkinson's &
Therapy Alzheimer's
• Migraine Management • Mood Disorders &
Psychopharmacology
• Anxiety Disorders & Sedatives • Herbal Supplements & Interactions
Page 1
, E XA M Q U EST I O N S
Q1 QUESTION 1 OF 107
Raloxifene (Evista) and bisphosphonates (alendronate, calcitonin)
RESPONSE
alternatives for hormone replacement therapy
RATIONALE
These medications are used as alternatives to hormone replacement therapy (HRT) for managing
osteoporosis. They work by inhibiting bone resorption, thereby preserving bone mineral density
and reducing fracture risk in postmenopausal women.
Q2 QUESTION 2 OF 107
Selective Estrogen Receptor Modulators (SERMs)
RESPONSE
Tamoxifen, toremifene, raloxifene -- provide estrogen benefits while avoiding its drawbacks
RATIONALE
Selective Estrogen Receptor Modulators (SERMs) are a class of drugs that exhibit tissue-specific
estrogenic or anti-estrogenic effects. They are exemplified by tamoxifen, toremifene, and
raloxifene, which act to provide beneficial estrogenic effects in some tissues while concurrently
blocking detrimental estrogenic actions in others. This dual action allows for therapeutic benefits
with reduced side effects.
Q3 QUESTION 3 OF 107
Dysfunctional uterine bleeding
RESPONSE
10-14 day course of progestin
Page 2
, RATIONALE
Progestin therapy is the cornerstone for managing dysfunctional uterine bleeding by stabilizing the
endometrium and preventing further excessive shedding. A 10-14 day course is typically prescribed
to restore hormonal balance and regulate the menstrual cycle. This intervention aims to reduce
bleeding volume and duration.
Q4 QUESTION 4 OF 107
Amenorrhea treatment
RESPONSE
progestin helps induce menstrual flow
RATIONALE
Progestin mimics the effects of progesterone, leading to the proliferation and subsequent
shedding of the uterine endometrium. This cyclical breakdown and shedding of the endometrium is
the physiological mechanism that results in menstrual flow, thereby inducing menstruation in cases
of amenorrhea.
Q5 QUESTION 5 OF 107
Amenorrhea estrogen levels are low
RESPONSE
give progestin for 5-10 days
RATIONALE
Low estrogen levels in amenorrhea indicate a hypogonadal state, often associated with
hypothalamic amenorrhea or premature ovarian failure. Administration of progestin for 5-10 days is
a diagnostic and therapeutic trial to assess for withdrawal bleeding, confirming adequate
endometrial proliferation from endogenous estrogen. If bleeding occurs, it suggests sufficient
estrogen priming.
Q6 QUESTION 6 OF 107
Long term progestin therapy
Page 3
, RESPONSE
protection against endometrial cancer
RATIONALE
Continuous progestin therapy opposes the proliferative effects of unopposed estrogen on the
endometrium. This antagonism prevents endometrial hyperplasia, thereby offering protection
against endometrial cancer in women receiving hormone therapy.
Q7 QUESTION 7 OF 107
Estradiol
RESPONSE
most active estrogenic compound. oral estrogen option
RATIONALE
Estradiol is the primary and most potent endogenous estrogen, responsible for most estrogenic
effects. It is also available as an oral medication for hormone replacement therapy.
Q8 QUESTION 8 OF 107
Advantages of estrogen transdermal patch
RESPONSE
lower total estrogen dose. less n/v. less fluctuation of estrogen blood levels. lower r/f DVT, PE
and stroke
RATIONALE
Transdermal estrogen delivery bypasses first-pass hepatic metabolism, allowing for a lower total
dose and reduced gastrointestinal side effects like nausea and vomiting. This route also provides
more stable serum estrogen levels and is associated with a decreased risk of thromboembolic
events and stroke compared to oral administration.
Q9 QUESTION 9 OF 107
Femring
Page 4
